Expression Analysis Hires Director of Business Development
News Sep 09, 2011
Jeff brings to Expression Analysis (EA) over a decade of successful sales and support experience with Affymetrix and RainDance Technologies.
While at RainDance, Jeff cultivated new business opportunities in research and clinical markets through the use of its sequence enrichment solutions in conjunction with various next generation sequencing platforms.
During his sales role at Affymetrix, he supported key genome and academic research centers in the use of expression, resequencing, and genotyping microarrays.
Prior to his commercial experience, Jeff sought to identify molecular markers responsible for tumor progression while performing research in the Department of Pathology at Brigham and Women’s Hospital and Harvard Medical School.
Jeff received his Bachelor of Science degree in Microbiology and Molecular Genetics from the University of Vermont.
“We are very pleased to have Jeff join us here at EA,” says Steve McPhail, CEO and President of Expression Analysis. “His experience and wealth of knowledge will greatly benefit the company as we continue to expand our services and customer base.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE